aldosterone has been researched along with ADPKD in 7 studies
Excerpt | Relevance | Reference |
---|---|---|
" To study the function and regulation of the aquaporin-2 water channel (AQP2) and the epithelial sodium channel (ENaC) in autosomal dominant polycystic kidney disease (ADPKD), we measured urinary excretion of AQP2 (u-AQP2), the β-subunit of ENaC (u-ENaC(β)), cAMP (u-cAMP), and prostaglandin E(2) (u-PGE(2)); free water clearance (C(H2O)); fractional sodium excretion (FE(Na)); and plasma vasopressin (p-AVP), renin (p-Renin), angiotensin II (p-ANG II), aldosterone (p-Aldo), and atrial and brain natriuretic peptide (p-ANP, p-BNP) in patients with ADPKD and healthy controls during 24-h urine collection and after hypertonic saline infusion during high sodium intake (HS; 300 mmol sodium/day) and low sodium intake (LS; 30 mmol sodium/day)." | 5.16 | Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion. ( Bech, JN; Graffe, CC; Lauridsen, TG; Pedersen, EB, 2012) |
"Eight borderline hypertensive ADPKD patients with (near) normal renal function and seven matched healthy control subjects were investigated at three levels of daily dietary sodium intake: 150, 50 and 450 mmol." | 1.29 | Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion. ( Barendregt, JN; Chang, PC; Florijn, KW; Muizert, Y, 1995) |
"We studied young adults with autosomal dominant polycystic kidney disease (ADPKD) to determine the characteristics that precede renal impairment." | 1.28 | Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. ( Briggs, JD; Davies, DL; Dominiczak, AF; Fraser, R; Harrap, SB; Macnicol, AM; Watson, ML; Wright, AF, 1991) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (57.14) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Malmberg, MH | 1 |
Mose, FH | 1 |
Pedersen, EB | 2 |
Bech, JN | 2 |
Torres, VE | 1 |
Abebe, KZ | 1 |
Chapman, AB | 2 |
Schrier, RW | 1 |
Braun, WE | 1 |
Steinman, TI | 1 |
Winklhofer, FT | 1 |
Brosnahan, G | 1 |
Czarnecki, PG | 1 |
Hogan, MC | 1 |
Miskulin, DC | 1 |
Rahbari-Oskoui, FF | 1 |
Grantham, JJ | 1 |
Harris, PC | 1 |
Flessner, MF | 1 |
Moore, CG | 1 |
Perrone, RD | 1 |
Graffe, CC | 1 |
Lauridsen, TG | 1 |
Barendregt, JN | 1 |
Florijn, KW | 1 |
Muizert, Y | 1 |
Chang, PC | 1 |
Gabow, PA | 1 |
Cerasola, G | 1 |
Li Vecchi, M | 1 |
Mulé, G | 1 |
Cottone, S | 1 |
Mangano, MT | 1 |
Andronico, G | 1 |
Contomo, A | 1 |
Parrino, IA | 1 |
Renda, F | 1 |
Pavone, G | 1 |
Scialabba, A | 1 |
Harrap, SB | 1 |
Davies, DL | 1 |
Macnicol, AM | 1 |
Dominiczak, AF | 1 |
Fraser, R | 1 |
Wright, AF | 1 |
Watson, ML | 1 |
Briggs, JD | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) or Other Cause of Chronic Renal Disease Compared to Healthy Volunteers[NCT04363554] | 51 participants (Actual) | Interventional | 2017-09-25 | Completed | |||
HALT Progression of Polycystic Kidney Disease Study B[NCT01885559] | Phase 3 | 486 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)
Intervention | annual percent change (Mean) |
---|---|
ACE-I + Placebo | 7.5 |
ACE-I + ARB | 7.3 |
Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up at 8 years (annually assessed)
Intervention | annual percent change (Mean) |
---|---|
ACE-I + Placebo | -8.8 |
ACE-I + ARB | -10.2 |
Report of back or flank pain since the last visit (yes or no) (NCT01885559)
Timeframe: 48 months
Intervention | percentage of participants at 48 months (Number) |
---|---|
ACE-I + Placebo | 43 |
ACE-I + ARB | 46 |
Cause-specific hospitalizations (cardiovascular) (NCT01885559)
Timeframe: up to 8 years
Intervention | events (Number) |
---|---|
ACE-I + Placebo | 29 |
ACE-I + ARB | 16 |
Hospitalization for any cause (NCT01885559)
Timeframe: up to 8 years
Intervention | events (Number) |
---|---|
ACE-I + Placebo | 173 |
ACE-I + ARB | 136 |
(NCT01885559)
Timeframe: Patients followed for 5-8 years with average of 6.5 years follow up
Intervention | participants (Number) |
---|---|
ACE-I + Placebo | 116 |
ACE-I + ARB | 115 |
Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)
Intervention | units on a scale per year (Mean) |
---|---|
ACE-I + Placebo | -0.031 |
ACE-I + ARB | -0.079 |
Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)
Intervention | units on a scale per year (Mean) |
---|---|
ACE-I + Placebo | -0.64 |
ACE-I + ARB | -0.68 |
1 review available for aldosterone and ADPKD
Article | Year |
---|---|
Hypertension in autosomal dominant polycystic kidney disease.
Topics: Aldosterone; Humans; Hypertension; Polycystic Kidney, Autosomal Dominant; Renal Circulation; Renin-A | 1997 |
2 trials available for aldosterone and ADPKD
Article | Year |
---|---|
Angiotensin blockade in late autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2014 |
Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Aquaporin 2; Atrial Natriuretic Factor; Chroni | 2012 |
4 other studies available for aldosterone and ADPKD
Article | Year |
---|---|
Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study.
Topics: Adult; Aged; Aldosterone; Aquaporin 2; Case-Control Studies; Epithelial Sodium Channels; Female; Hum | 2020 |
Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dihydroxyphenylalanine | 1995 |
Role of renin-angiotensin-aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease.
Topics: Aldosterone; Blood Pressure; Catecholamines; Female; Humans; Hypertension; Hypertension, Renal; Male | 1997 |
Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aldosterone; Atrial Natriuretic Factor; Dietary Proteins | 1991 |